Home›Trial›NCT05103254
NCT05103254RECRUITING

Bempedoic Acid Pregnancy Surveillance Program

Study Summary

Bempedoic acid pregnancy surveillance program

Conditions
PregnancyHyperlipidemias
Interventions / Drugs
Bempedoic AcidBempedoic Acid / Ezetimibe
View on ClinicalTrials.gov ↗
Sponsor
ESPR
Esperion Therapeutics
Cardiovascular
D40/100
Study Details
Enrollment20 participants
Primary Completion—
Lead SponsorEsperion Therapeutics, Inc.
Data Retrieved2026-04-11 04:13:10.912702+00:00
What This Trial Means for Biotech Investors
Trial Phase Context
Status & Expected Data

Currently recruiting: the trial is enrolling patients. A data readout is not expected until after enrollment closes and the follow-up period is complete.

Enrolled: 20 participants
Sponsor Catalyst Profile

Esperion Therapeutics (ESPR) is the sponsoring company for this trial. BiotechSign currently grades this company D (40/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

ESPR Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.